RG6627
/ Roche, Ionis
- LARVOL DELTA
Home
Next
Prev
1 to 6
Of
6
Go to page
1
September 03, 2026
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7812653 in Participants With Early Symptomatic Alzheimer's Disease (eAD)
(clinicaltrials.gov)
- P1 | N=6 | Active, not recruiting | Sponsor: Hoffmann-La Roche | Recruiting ➔ Active, not recruiting | N=50 ➔ 6 | Trial completion date: May 2030 ➔ Mar 2027 | Trial primary completion date: Dec 2029 ➔ Mar 2027
Enrollment change • Enrollment closed • Trial completion date • Trial primary completion date • Alzheimer's Disease • CNS Disorders
July 30, 2026
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7812653 in Participants With Early Symptomatic Alzheimer's Disease (eAD)
(clinicaltrials.gov)
- P1 | N=50 | Recruiting | Sponsor: Hoffmann-La Roche | Trial primary completion date: Apr 2028 ➔ Dec 2029
Trial primary completion date • Alzheimer's Disease • CNS Disorders
February 23, 2026
BP45770: First-in-Human Study of RO7812653
(clinicaltrialsregister.eu)
- P1 | N=117 | Recruiting | Sponsor: F. Hoffmann-La Roche AG | Not yet recruiting ➔ Recruiting
Enrollment open • First-in-human • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Dementia
February 18, 2026
BP45770: First-in-Human Study of RO7812653
(clinicaltrialsregister.eu)
- P1 | N=117 | Not yet recruiting | Sponsor: F. Hoffmann-La Roche AG
First-in-human • New P1 trial • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Dementia
February 06, 2026
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7812653 in Participants With Early Symptomatic Alzheimer's Disease (eAD)
(clinicaltrials.gov)
- P1 | N=50 | Recruiting | Sponsor: Hoffmann-La Roche | Not yet recruiting ➔ Recruiting
Enrollment open • Alzheimer's Disease • CNS Disorders
November 20, 2025
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7812653 in Participants With Early Symptomatic Alzheimer's Disease (eAD)
(clinicaltrials.gov)
- P1 | N=50 | Not yet recruiting | Sponsor: Hoffmann-La Roche
New P1 trial • Alzheimer's Disease • CNS Disorders
1 to 6
Of
6
Go to page
1